01—Abstract
Summary
Summary of the 8-K filed March 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) filed a Form 8-K on March 12, 2026 to announce the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026.
Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO, for which it has engaged a leading executive search firm. He will remain in the role until a permanent CFO is appointed. Mr. Ramsay previously served as the Company's CFO from 2003 to 2009 and again from 2013 to 2015, and as Vice President, Corporate Development from 2009 to 2013.
Since April 2017 he has served on the board of Savara Inc., and he was previously Senior Vice President and CFO of Bonti, Inc. until its acquisition by Allergan plc in October 2018. The filing states that he has no family relationships with any director or executive officer and no material interest in any Company transaction. Compensation under the arrangement is a monthly salary of $50,000,a plus an initial grant of 10,000 restricted stock units (RSUs) vesting on June 30, 2026, and an additional 2,500 RSUs granted if he is still Interim CFO on July 1, 2026.
Both grants fall under the 2021 Stock Plan and carry a one-year holding period after vesting. The filing also notes that the forward-looking statements in the press release cite potential delays in hiring a permanent CFO as a risk factor.
02—Key points
Key Highlights
- David Ramsay appointed Interim Chief Financial Officer, effective March 23, 2026, overseeing all financial operations
- Permanent CFO search is underway, with a leading executive search firm engaged; Ramsay remains until a permanent CFO is named
- Ramsay is a returning executive who previously served as CFO from 2003 to 2009 and from 2013 to 2015
- Compensation: $50,000 monthly salary plus 10,000 RSUs vesting June 30, 2026, and 2,500 additional RSUs if still serving on July 1, 2026
- RSUs are granted under the 2021 Stock Plan, with a one-year holding period after vesting
- CEO Dr. Helen Torley praised Ramsay's capital markets, investor relations and Halozyme-specific experience
- Filing discloses no family relationships and no material interest in Company transactions for Ramsay
03—Questions
Frequently Asked Questions
Who is David Ramsay and what is his relevant experience?
Ramsay previously served as Halozyme's CFO from 2003 to 2009 and from 2013 to 2015, and as Vice President, Corporate Development from 2009 to 2013. He was also Senior Vice President and CFO of Bonti, Inc. from February 2018 until its acquisition by Allergan plc in October 2018, and has served on the board of Savara Inc. since April 2017. The filing states he holds a B.S. from UC Berkeley and an M.B.A. from The Wharton School.
How long will Ramsay serve as Interim CFO?
He will remain in the role until a permanent CFO is appointed. The company says its executive search for a permanent CFO is well underway.
What compensation will Ramsay receive?
He will receive a monthly salary of $50,000 and an equity grant of 10,000 RSUs vesting June 30, 2026, provided he remains employed through that date. If he is still Interim CFO on July 1, 2026, he will receive an additional 2,500 RSUs vesting on his employment termination date. Both grants are subject to a one-year holding period after vesting.
Are there any conflicts of interest or related-party concerns?
The filing states there are no family relationships between Ramsay and any director, executive officer, or nominee, and that he has no direct or indirect material interest in any transaction or arrangement in which the Company is a participant.
What risks does the company identify related to this change?
The press release's forward-looking statements identify potential delays in hiring a permanent chief financial officer as a factor that could cause actual results to differ materially from expectations.
04—Continue